Coherus Oncology (CHRS) Short term Debt (2014 - 2025)

Coherus Oncology has disclosed Short term Debt across 8 years of filings, most recently posting $26.2 million for Q1 2025.

• Short term Debt for Q1 2025 came in at $26.2 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2025 was $26.2 million (changed N/A YoY), and the FY2024 annual result was $13.6 million, up 312.73% from the prior year.
• Short term Debt came in at $26.2 million for Q1 2025 at Coherus Oncology, up from $13.6 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $26.2 million in Q1 2025 to a low of $90000.0 in Q2 2023.
• The 4-year median for Short term Debt is $9.2 million (2024), against an average of $9.5 million.
• Peak annual rise in Short term Debt reached 10124.44% in 2024, while the deepest fall reached 127.77% in 2024.
• Coherus Oncology's Short term Debt stood at $17.3 million in 2021, then slumped by 80.93% to $3.3 million in 2023, then jumped by 312.73% to $13.6 million in 2024, then soared by 92.57% to $26.2 million in 2025.
• The last three Short term Debt figures came in at $26.2 million (Q1 2025), $13.6 million (Q4 2024), and $9.2 million (Q3 2024), per Business Quant data.